Compare AstraZeneca plc (AZN) vs Sibanye Stillwater Ltd (SBSW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Sibanye Stillwater Ltd — how do they compare? AstraZeneca plc trades at $158.4 (market cap $248.14B), while Sibanye Stillwater Ltd trades at $10.64 (market cap $7.54B). The key difference: AstraZeneca plc is far larger — about 32.9× Sibanye Stillwater Ltd's market cap, and Sibanye Stillwater Ltd pays the higher dividend (2.93%). Which is the better fit depends on your goals.
| AZN | SBSW | |
|---|---|---|
Market Cap | $248.14B | $7.54B |
Sector | Health | Basic Materials |
52-Week High | $209.48 | $21.12 |
52-Week Low | $147.06 | $7.27 |
Enterprise Value | $275.41B | $9.19B |
Dividend Yield | 2.01% | 2.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $158.48, down 2.12% amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth from $54.1B in 2024 to $58.7B in 2025 and net income reaching $10.2B. Recent earnings beats and a 47.5% analyst buy rating contrast with technical indicators showing oversold conditions near key support at $155.
Investment outlook remains positive based on earnings momentum and valuation metrics (P/E 23.76), though risks include potential merger integration challenges and ongoing legal investigations. The company's robust cash flow generation and dividend payments provide shareholder value support despite near-term volatility.
Sibanye Stillwater (SBSW) trades at $10.77, up 0.94% with a bullish technical signal. Despite negative profitability metrics, the stock shows attractive valuation with P/E of 4.76 and P/S of 0.94. Recent earnings misses contrast with improved cash flow projections for 2025. Analyst consensus is mixed with 42.9% buy ratings and $14.25 price target, suggesting 32% upside potential.
The stock presents a value opportunity with deep undervaluation but carries significant execution risk. Key catalysts include debt reduction initiatives and commodity price recovery, while persistent negative margins and volatile earnings remain concerns. Institutional sentiment leans cautiously optimistic given the substantial discount to analyst targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Sibanye Stillwater Ltd
Sibanye Stillwater Ltd is a South Africa-focused mining company. The Group currently owns and operates five underground and surface gold operations in South Africa: the Cooke, DRDGOLD, Driefontein, and Kloof operations in the West Witwatersrand region, and the Beatrix Operation in the southern Free State province. In addition to mining, the company owns and manages extraction and processing facilities at its operations, where gold-bearing ore is treated and beneficiated to produce gold dore. The gold dore is further refined at Rand Refinery into gold bars with a purity of at least 99.5% and is then sold on international markets. Sibanye holds a 44% interest in Rand Refinery, global refiners of gold, and the largest in Africa. Rand Refinery markets gold to customers around the world.
Read more on SBSW →
